Trial Profile
A study to evaluate the orexigenic ghrelin secretion in HCV-infected patients with telaprevir- or simeprevir-based triple therapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 19 Dec 2015
Price :
$35
*
At a glance
- Drugs Simeprevir (Primary) ; Telaprevir (Primary) ; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Pharmacodynamics
- 19 Dec 2015 New trial record